Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.
Lancet Diabetes Endocrinol. 2022 Feb;10(2):129-141. doi: 10.1016/S2213-8587(21)00285-0. Epub 2021 Dec 22.
Subclinical hypothyroidism, which is defined as a thyroid-stimulating hormone concentration higher than the reference range (generally 4·5 mIU/L or higher) with normal free thyroxine concentrations, is frequently found in older individuals. International guidelines differ in recommendations for management of subclinical hypothyroidism in older individuals. We assessed published data during the past decade on the clinical significance and treatment of subclinical hypothyroidism in individuals aged 65 years and older. Meta-analyses, randomised clinical trials, and cohort studies are discussed in this narrative Review. Studies showed no significantly increased incidence in adverse cardiovascular, musculoskeletal, or cognitive outcomes in individuals aged 65 years or older when serum thyroid-stimulating hormone concentration was 4·5-7·0 mIU/L versus a euthyroid group. Moreover, in older individuals with subclinical hypothyroidism, symptoms of hypothyroidism and cardiac and bone parameters did not improve after levothyroxine treatment. These data suggest that treatment with levothyroxine should be considered for individuals aged 65 years or older with subclinical hypothyroidism when thyroid-stimulating hormone concentration is persistently 7 mIU/L or higher and to not initiate treatment with thyroid-stimulating hormone concentrations of less than 7 mIU/L. Levothyroxine doses should be personalised according to age, comorbidities, and life expectancy.
亚临床甲状腺功能减退症定义为促甲状腺激素浓度高于参考范围(通常为 4.5 mIU/L 或更高),同时游离甲状腺素浓度正常。这种情况在老年人中较为常见。国际指南在老年人亚临床甲状腺功能减退症的管理建议上存在差异。我们评估了过去十年中关于 65 岁及以上人群亚临床甲状腺功能减退症的临床意义和治疗的已发表数据。本综述讨论了荟萃分析、随机临床试验和队列研究。研究表明,血清促甲状腺激素浓度在 4.5-7.0 mIU/L 与甲状腺功能正常组相比,65 岁及以上人群发生不良心血管、肌肉骨骼或认知结局的发生率并没有显著增加。此外,在亚临床甲状腺功能减退的老年患者中,甲状腺功能减退的症状以及心脏和骨骼参数在接受左甲状腺素治疗后并未改善。这些数据表明,对于促甲状腺激素浓度持续高于 7 mIU/L 的 65 岁及以上亚临床甲状腺功能减退症患者,应考虑使用左甲状腺素进行治疗,而促甲状腺激素浓度低于 7 mIU/L 时不应开始治疗。左甲状腺素的剂量应根据年龄、合并症和预期寿命进行个体化。